Document is current

Article History

Received: 11 May 2023

Accepted: 22 October 2023

First Online: 17 November 2023

Declarations

:

: A. Tufman receives travel support from Pfizer and Amgen. C. Belka eceives grants or contracts from any entity but not related to this manuscript from Viewray, Brainlab and ELEKTA. C. Belka receives honoraria from BMS, ROCHE, MERCK, Astrazeneca and Viewray. C. Belka receives support for attending meetings and/or travel from BMS, ROCHE, MERCK, Astrazeneca and Viewray. C. Belka receives BMS, ROCHE, MERCK, Astrazeneca and Viewray. C. Belka serves in a fiduciary role in the ESTRO. C. Eze receives grants or contracts from any entity but not related to this manuscript from German Cancer Aid. C. Eze receives consulting fees from Novartis. C. Eze receives support for attending meetings and/or travel from Novartis. F. Manapov receives an unrestricted Research Institutional Grant from AstraZeneca. F. Manapov receives honoraria from AstraZeneca, Novartis, Roche, Lilly, Elekta and Brainlab. F. Manapov serves in the advisory board of AstraZeneca, Novartis. L. Käsmann receives honoraria from AMGEN. N. Reinmuth reports receiving honoraria for speaker activities and participation in advisory boards for AbbVie, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche, and Takeda. K. Hofstetter, J. Taugner, S. Mansoorian, B. Flörsch and T. Duell declare that they have no competing interests.

: All patients gave express written informed consent. This retrospective analysis is in compliance with the principles of the Declaration of Helsinki and its subsequent amendments. This work was approved by the Ethics Committee of the Ludwig Maximilian University of Munich (reference number: 17-230).